and from the overall investment activity of the Initial Purchaser [GS & Co], including in other transactions with
the Issuer [Hudson 1/2 Ltd].” (Id.)
Dodona’s Complaint does not rest on allegations that those overt statements were, standing alone, false, but ra-
reason or reasons why the statement is misleading.” 15 U.S.C. § 78u–4(b).
However, since Dodona‘s allegations of misrepresentation sound in omission, the question remains whether the
Marketing Defendants had a duty to disclose either of the omissions alleged; and, if so, whether disclosures or pub-
licly available information discharged them of that duty. See In re Time Warner Inc. Sec. Litig., 9 F.3d at 267 (“an
omission is actionable under the securities law only when the [defendant] is subject to a duty to disclose the omitted
investment and risk-management “strategy,” or how the Hudson CDOs might fit into some overarching plan. Nor
are there any independent statutory or regulatory disclosure obligations that would have required the Marketing De-
fendants to reveal such a strategy. See In re Morgan Stanley Info. Fund Sec. Litig., 592 F.3d 347, 360 (2d Cir.2010)
(failure to meet “[a]ffirmative [d]isclosure [o]bligations” is one form of omission that can create federal securities
law liability). Since “[s]ilence, absent a duty to disclose, is not misleading under Rule 10b–5,” Basic Inc., 485 U.S.
in its entirety, it is clear that the alleged omission amounts to an allegation that Defendants inaccurately represented
the risk, of which they were actually aware, associated with investing in the Hudson CDOs. Contrary to Defendants‘
contentions, the alleged omission is therefore more substantial than a failure to disclose “mere disbelief” or “opin-
ions.” (Def. Br. at 17–19 (Docket No. 49).) Since the Offering Circulars contained affirmative representations re–
garding the risks of investing,FN12 the Marketing Defendants had a duty to ensure that those statements were accurate
ments of SEC Rule 144A (“Rule 144A”), 17 C.F.R. § 230.144A, which exempts registration for sales of re-
stricted or controlled securities to “Qualified Institutional Buyers.” Rule 144A does not require risk disclo-
sures, but the Offering Circulars made them anyway.
Dodona has adequately alleged an actionable omission because, assuming it is right about the known risks, the
risk disclosures in the Offering Circulars were inaccurate and therefore misleading. The Goldman-authored emails